Skip to content
Search

Latest Stories

JLR retail sales up on strong demand

Retail sales in the fourth quarter were 32 per cent higher in the UK

JLR retail sales up on strong demand

TATA MOTORS-owned Jaguar Land Rover on Monday (8) reported a 22 per cent year-on-year increase in its retail sales at 431,733 units for fiscal ended March 31, 2024.

During the last fiscal, the company's wholesales rose 25 per cent to 401,303 units against 2022-23 financial year, Tata Motors said in a regulatory filing.


The wholesale volumes and retail sales of the UK-based automaker were higher in all regions as compared to the preceding year, it added.

JLR wholesales in the fourth quarter stood at 110,190 units, up 16 per cent as against it was a year ago.

Retail sales in the January-March quarter stood at 114,038 units, up 11 per cent from FY23.

Compared to the prior year, retail sales in the quarter were 32 per cent higher in the UK, 21 per cent in North America, and 16 per cent in the Overseas region.

Meanwhile, retail sales in China and Europe fell 9 per cent and 2 per cent, respectively in the fourth quarter over FY23.

By brand, compared to the prior year, wholesale volumes increased in the fourth quarter for Range Rover (up 22 per cent to 58,280 units), Defender (up 5 per cent to 28,702 units), Jaguar (up 39 per cent to 13,528 units) and Discovery (up 1 per cent to 9,680 units), the company said.

Last month, Tata Motors said it will split into two listed entities and separate its commercial vehicles business from its passenger vehicles arm, which houses the JLR business.

(Agencies)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less